DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for congenital hypothyroidism — screening already-approved drugs against its 15-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCongenital hypothyroidism maps to a 15-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedLevothyroxineApproved drug
Structures already discussed alongside congenital hypothyroidism in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
TRANSTHYRETIN THR119MET PROTEIN STABILISATION — Levothyroxine has a real, experimentally solved structure in complex with this target (PDB 1F86, 1.1 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet t44drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1F86 · 1.1 Å · ligand Levothyroxine (T44). Experimental structure, not a prediction.
What the evidence adds up to
Primary congenital hypothyroidism is the most common neonatal endocrine disorder. It can be subdivided into thyroid dysgenesis, meaning abnormal thyroid development, and dyshormonogenesis, where a defective thyroid hormone biosynthesis pathway results in inadequate hormone production despite a structurally intact gland. Delayed treatment of neonatal hypothyroidism may result in irreversible neurodevelopmental impairment. Screening programs facilitate prompt diagnosis where available, but the molecular basis for primary congenital hypothyroidism remains unclear in most cases. A 2025 review summarises current understanding of the genetic etiologies, including classical genetic causes in the context of normal thyroid physiology, genes recently reported to play a role in pathogenesis, and novel genomic mechanisms.
A 2023 consensus article states that congenital hypothyroidism is one of the most treatable endocrine disorders in infants and children and that on-time diagnosis and treatment can prevent the adverse effects of thyroid hormone deficiency on neurodevelopment. The article notes there are many challenges in screening, post-screening, diagnosis, and management. The authors created a national approach based on the conditions of their country, but the abstract does not report any specific efficacy data, response rates, or survival numbers.
A 1986 study of 22 children with congenital hypothyroidism found that their disease was recognised on clinical grounds and confirmed by laboratory tests, but diagnosis was usually late, most frequently after several years. In that cohort, 95% had neurologic disturbances of variable severity, 91% had sub-normal IQ, and 59% required special education. These results are plainly disappointing and reflect the consequences of delayed diagnosis.
What is still missing is a clear molecular diagnosis for most cases, which limits the ability to stratify patients by genetic cause. The 2023 consensus acknowledges challenges in screening and management but does not provide data from a controlled trial. No randomised trial design or funding for such a trial is described in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Acta Paediatrica · 1988 · 63 citations
Congenital Hypothyroid Goiter and Amiodarone
AbstractAmiodarone is an anti-arrhythmic drug with a content of 39% Iodine. No adverse effects on fetal thyroid function have previously been observed with maternal ingestion of Amiodarone during pregnancy. A case of severe congenital hypothyroidism with goiter, associated with maternal ingestion of 200 mg Amiodarone daily from the 13th week of pregnancy, is described here. No other environmental causes of goiter, nor a congenital organic thyroid disorder could be demonstrated.
European Thyroid Journal · 2025 · 16 citations · open access
Genetics of primary congenital hypothyroidism: three decades of discoveries and persisting etiological challenges
AbstractPrimary congenital hypothyroidism (CH) is the most common neonatal endocrine disorder, and may be etiologically subdivided into thyroid dysgenesis, referring to abnormal thyroid development, and dyshormonogenesis, where a defective thyroid hormone biosynthesis pathway results in inadequate hormone production despite a structurally intact gland. Delayed treatment of neonatal hypothyroidism may result in irreversible neurodevelopmental impairment; therefore, where available, CH screening programs facilitate prompt diagnosis. However, the molecular basis for CH remains unclear in most of the cases. This review summarizes current understanding of the genetic etiologies underlying primary CH and associated phenotypes. Classical genetic causes are discussed in the context of their role in normal thyroid physiology. Genes recently reported to play a role in the pathogenesis of CH are discussed, and novel genomic mechanisms in CH are described.
International Journal of Preventive Medicine · 2023 · 7 citations · open access
The Consensus on the Diagnosis and Management of Congenital Hypothyroidism in Term Neonates
AbstractCongenital hypothyroidism (CH) is one of the most treatable endocrine disorders in infants and children that can influence the function of many organs in the body. On-time diagnosis and treatment can prevent the adverse effects of thyroid hormone deficiency on the child's neurodevelopment. There are many challenges in screening, post-screening, diagnosis, and managing this disorder. Therefore, this article aimed to mention updated information on this issue. Although there are different approaches for the treatment of hypothyroidism, the authors decided to create a national approach based on the conditions of our country.
Boletín Médico del Hospital Infantil de México · 2015 · 6 citations · open access
Hipotiroidismo congénito
AbstractEl hipotiroidismo congénito (HC) es una causa prevenible de retraso mental, por lo que es de suma importancia que el diagnóstico y tratamiento oportunos sean realizados por el médico de primer contacto. El tamizaje para HC se debe realizar entre el segundo y quinto días de vida, con sangre capilar mediante la punción del talón. Debe confirmarse mediante el perfil tiroideo en sangre venosa. La etiología más frecuente es la disgenesia tiroidea, la cual se identifica con gamagrafía tiroidea antes de iniciar el tratamiento. El tratamiento es con levotiroxina (10-15 μg/kg/día) y no debe ser retrasado ni suspendido durante los tres primeros años de vida debido al efecto deletéreo en el neurodesarrollo en el caso de deficiencia de hormonas tiroideas durante esta etapa. Los recién nacidos prematuros, enfermos o con síndrome de Down requieren una valoración especial. En este artículo se describen los algoritmos diagnósticos y terapéuticos del HC. Congenital hypothyroidism (CH) is a cause of preventable mental retardation; therefore, timely diagnosis and treatment by the primary care physician is very important. CH screening must be performed between the second and fifth days of life with capillary blood done with a heel prick and must be confirmed by measurement of thyroid hormones in venous blood. The most common cause of CH is thyroid dysgenesis, which may be identified by a thyroid scan carried out before initiating treatment. Treatment should be with levothyroxine (10-15 μg/kg/day) and should not be delayed or suspended during the first 3 years of life due to the deleterious effect on neurodevelopment in case of low thyroid hormones during this time. Preterm or sick infants or those with Down syndrome require special consideration. This article provides diagnostic and therapeutic algorithms for CH.
Thyroid Research and Practice · 2013 · 4 citations
Congenital hypothyroidism: Its profile in infancy
AbstractThyroid hormones play an important role in the physical development, neuronal growth and influence various metabolic processes of the newborn. Their deficiency or a defect in thyroid hormone receptor activity may present as congenital hypothyroidism. This may lead to irreversible mental and physical growth retardation. Interestingly majority of the neonates with congenital hypothyroidism appear to be normal. These facts led us to review this entity in infancy. Therefore, initiation of early treatment becomes essential. Levothyroxine is the drug of choice and its dosage should be adjusted with biochemical hormone assays. The untoward effects of congenital hypothyroidism are largely reversible, if treated before the age of 6 weeks, a very easily affordable help in curtailing the morbidity among these newborns. Genetic counseling and routine examination of siblings is very essential.
Revista chilena de pediatría · 1986 · 1 citations · open access
Hipotiroidismo congénito Evaluación neurológica y sicométrica
AbstractTwenty two children with congenital hypothyroidism (CHT) were studied in order to evaluate the occurrence of neurologic damage. Their disease was recognized on clinical grounds and subsequently confirmed by laboratory tests and diagnosis was dones usually late, most frecuently after several years, thus 95% of our cases had neurologic disturbances of variable severity, 91%had sub-normal IQ and 59%required special education.
Early Diagnosis and Prognosis in Congenital Hypothyroidism
AbstractCongenital hypothyroidism is a preventable cause of mental retardation and in most instances can be diagnosed in the first six months of life.The pessimism often expressed concerning the prognosis in these cases has led to an erroneous belief that early diagnosis and treatment are relatively unimportant. To obtain the best possible results with therapy, diagnosis must be early and treatment must be adequate.Insufficient emphasis has been placed on several early symptoms and signs which, though not specific for congenital hypothyroidism, should arouse suspicion of the condition. Laboratory determinations to confirm the diagnosis of congenital hypothyroidism are generally available.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
